Arcutis Biotherapeutics shared new data on its topical drug ZORYVE (roflumilast) at major dermatology conferences, highlighting its effectiveness in infants with atopic dermatitis and in treating psoriasis, including sensitive areas like the scalp and genitals. The company also presented research on seborrheic dermatitis inflammation and real-world studies on long-term topical corticosteroid use, revealing patient concerns and adverse effects. These findings support ZORYVE's expanding role in managing chronic inflammatory skin conditions and underscore the need for safer long-term treatments. The FDA is reviewing ZORYVE for infants aged 3 to less than 24 months, with a decision expected in February 2027.
Arcutis Biotherapeutics and its ZORYVE topical drug data are the subject, with Pluang's health sector market snapshot as of Oct 09, 2026 18:51 WIB: Of 128 priced health-sector US stocks tradable on Pluang, 71 rose and 49 fell today. Notable movers include BIO at USD 375.02 with a 1-day change of +4.06%, DFTX at USD 35.53 with a 1-day change of +3.95% and 100% buy order activity, and HRTX at USD 0.37 with a 1-day change of +3.29%. The most notable figure is BIO's price at USD 375.02.
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
Fast Retailing reported FY26 earnings per share 6% above consensus, fueled by a 26.2% surge in UNIQLO's international sales, especially a 38.7% increase in Europe. Western markets now generate more revenue than Greater China for the brand. The compan...
Bitcoin's price remains stable around $82,500 even as reports emerge about a theft involving Ledger, a popular crypto hardware wallet provider. This resilience suggests investor confidence in Bitcoin's value despite security concerns in the crypto sp...
Bitcoin briefly fell below $81,000 before recovering to around $82,500, triggered by $1.09 billion in forced liquidations of leveraged crypto positions, mostly from traders betting on price increases. This sell-off added pressure on digital assets, c...
Bitcoin's price fell from about $85.7K to $82.5K, triggering over $2.4 billion in liquidations mostly on long positions. The decline coincided with rising US Treasury yields above 5.3%, higher oil prices, and significant outflows from Bitcoin ETFs, r...
